FDA Compounding Policy: What It Means for Research Peptide Supply

The FDA compounding landscape for peptide compounds shifted materially during 2024 and 2025, and the consequences for the research-use-only supply market are clearer now than they were 12 months ago. The short version: enforcement discretion that previously allowed compounding pharmacies to prepare versions of Semaglutide and Tirzepatide during the GLP-1 shortage period ended. The shortages got resolved on the FDA Drug Shortage Database. Transition deadlines were set. Compounding pathways for those specific drugs narrowed substantially. Separately, several peptides went through the Pharmacy Compounding Advisory Committee under the section 503A bulk drug substance review process, and some got category 2 or category 3 placements that effectively restrict their use in 503A compounding for human use. This article walks through what changed at the regulatory level and what it means for the research-use-only supply market that serves academic laboratories and institutional research. Important framing: this is a regulatory and supply-market discussion only. Nothing here is human-use guidance, dosing guidance, or clinical advice. Research-use-only material occupies a separate regulatory category from compounded drug products. Retatrutide, MOTS-c, and BPC-157 are supplied at originlabsresearch.com as research-use-only material for institutional preclinical work, and the discussion below covers the regulatory context that surrounds (but does not restrict) that supply.

Section 503A and the bulk drug substances list

Section 503A of the Federal Food, Drug, and Cosmetic Act sets the framework under which licensed pharmacists and physicians may compound drug products for individual patients in response to valid prescriptions.

For a bulk drug substance to be used in 503A compounding, it must meet one of three conditions:

• Be the subject of a United States Pharmacopeia or National Formulary monograph.
• Be a component of an FDA-approved drug.
• Appear on a list of bulk drug substances developed by the FDA following review by the Pharmacy Compounding Advisory Committee (PCAC).

The PCAC holds public meetings to consider nominated substances and recommends whether each should be placed on:

• Category 1: suitable for compounding.
• Category 2: with concerns.
• Category 3: not suitable.

Several peptide substances have gone through formal advisory committee review and Federal Register notices during 2023 to 2025. Some nominations resulted in category 2 or category 3 placements that effectively restrict their availability for 503A pharmacy compounding for human use. The category placements draw on the advisory committee's review of published clinical literature, safety data, and the existence of comparable approved drug products.

The PCAC proceedings are public. The transcripts and supporting materials provide a detailed record of the regulatory reasoning applied to each nominated peptide.

The GLP-1 shortage, enforcement discretion, and its end

Parallel to the 503A bulk substance process, the GLP-1 and incretin agonist shortage that started in 2022 and ran into 2024 created a separate regulatory situation.

During the documented shortage period, FDA exercised enforcement discretion that permitted certain compounding pharmacies and outsourcing facilities to prepare compounded versions of Semaglutide and Tirzepatide for human prescription use, subject to specified conditions.

What changed in late 2024 and through 2025:

• The shortages were resolved on the FDA Drug Shortage Database.
• The agency issued formal notices announcing resolution and indicating that the enforcement discretion period would end on specified deadlines.
• Compounding pharmacies and outsourcing facilities were given transition windows to wind down compounding activities for these specific compounds.
• The shortage resolution drew substantial industry attention and was the subject of litigation by trade associations representing compounders.
• Litigation outcomes through 2025 generally supported the FDA's authority to make the shortage resolution determinations under the existing statutory framework.

As of mid-2026, the result is a substantially narrower legal pathway for compounding pharmacies to produce GLP-1 and incretin agonist drug products for human prescription use in the United States. Retatrutide is in a different regulatory bucket again, since it has not been approved and is not on a shortage list, but the broader regulatory context for the incretin class has shifted.

Research-use-only material is a separate regulatory category

This is the key distinction that often gets blurred.

Research-use-only material:

• Supplied to investigators for laboratory research (in vitro, cell culture, animal studies).
• Not represented as a drug.
• Not intended for human therapeutic use.
• Not subject to the same regulatory framework as compounded drug products.

Compounded drug products:

• Prepared for individual patient prescriptions under section 503A.
• Or produced in larger quantities under section 503B outsourcing facility rules.
• Subject to the 503A bulk substance list and PCAC review process.

The boundary between research-use-only material and a drug product is defined by representations made about the material and the intended use. Material represented for human use, labelled with human dosing instructions, or marketed for therapeutic indications is treated as a drug, regardless of the chemical identity of the substance. Material supplied with research-use-only labelling, not represented for human therapeutic use, and intended for laboratory research is treated as research material.

This distinction has been reaffirmed in FDA enforcement actions, warning letters, and industry guidance over many years.

Research peptide suppliers operating within the research-use-only framework typically maintain clear labelling on all material, certificate of analysis documentation, and customer agreements that affirm the research-only intended use. The regulatory tightening on compounding pathways for specific peptide compounds does not extend to or restrict the supply of research-use-only material, provided the supplier maintains that distinction.

What the 2024 to 2026 changes mean for the research peptide supply market

Practical implications for the research-use-only market:

• The legal compounding market for GLP-1 and incretin agonist drug products narrowed substantially. That is a compounding-for-human-use story, not a research-use-only story.
• The research-use-only market for these compounds continues to operate as a separate regulatory category and remains available to qualified researchers under the research-use-only framework. MOTS-c, BPC-157, and Retatrutide all sit in that bucket.
• Category 2 or category 3 PCAC placements for specific peptides clarify their status for compounding for human use without affecting the research-use-only framework for laboratory purchasers.
• FDA enforcement attention has focused on the boundary between research-use-only material and material represented for human therapeutic use. Actors who blur this distinction by marketing research material with human dosing claims or therapeutic representations have been targets of enforcement actions.
• Supplier practices matter. Clear research-use-only labelling, accurate certificate of analysis documentation, and customer agreements that affirm research-only intended use have become the baseline for suppliers operating cleanly within the research category.
• Some suppliers have reviewed their labelling, marketing, and customer-facing language to ensure clear alignment with the research-use-only category.

Suppliers operating clearly within the research-use-only framework have continued to serve the academic and institutional research market without the regulatory restrictions that apply to compounding for human prescription use.

What researchers and suppliers should monitor going forward

Tracking the regulatory environment through 2026 to 2027:

• PCAC meeting schedule. The committee continues to hold periodic meetings. Federal Register notices for upcoming meetings are the primary source of advance information on category placement decisions.
• FDA Drug Shortage Database. Any future shortages or shortage resolutions involving peptide drugs could prompt additional enforcement discretion changes or enforcement priority shifts.
• FDA warning letters and enforcement actions. The published warning letter database is searchable for peptide-related actions and remains a primary signal of where the agency is focusing attention.
• Industry trade publications and association communications. Often the earliest indication of regulatory developments and litigation outcomes affecting the compounding and research peptide markets.
• Institutional review and biosafety requirements. The broader framework for research material continues to evolve and should be monitored by institutional research administrators.

Material supplied at originlabsresearch.com is supplied for research purposes only and is not represented for human or veterinary therapeutic use. End users are responsible for compliance with applicable institutional, state, and federal regulations governing research material. The discussion above is for regulatory orientation only and does not constitute legal advice for any specific factual situation.

References

1. [1] United States Food and Drug Administration (2024). Compounding and the Drug Quality and Security Act: section 503A and 503B regulatory framework. FDA Guidance Documents.
2. [2] United States Food and Drug Administration Pharmacy Compounding Advisory Committee (2023). Meeting transcripts and supporting materials, bulk drug substances nominated for inclusion on the 503A bulks list. FDA Advisory Committee Materials.
3. [3] Lipworth AD, Hey SP, Kesselheim AS (2020). Regulatory pathways for the introduction of new drugs into pharmacies. Annals of Internal Medicine. PMID 32479182
4. [4] United States Food and Drug Administration (2024). Resolution of drug shortages and end of enforcement discretion for compounded versions of approved GLP-1 and dual incretin agonist drug products. FDA Drug Shortage Database Notices.
5. [5] Outterson K (2012). Regulating compounding pharmacies after NECC. New England Journal of Medicine. PMID 23193962

Frequently asked questions